Xeltis

R&D

Paulo Neves, CMO of Xeltis, discusses transformative implants that enable the natural creation of living and long-lasting vessels.

News

Scholar Rock has won its first product approval, on its second attempt, as the FDA gives a green light to its spinal muscular atrophy drug Isembyld.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.